Advertisement

Estrogen and dementia

  • Walter A. Rocca
    Correspondence
    Corresponding author at: Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
    Affiliations
    Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

    Department of Neurology, Mayo Clinic, Rochester, MN, USA

    Women's Health Research Center, Mayo Clinic, Rochester, MN, USA
    Search for articles by this author
  • Stephanie S. Faubion
    Affiliations
    Women's Health Research Center, Mayo Clinic, Rochester, MN, USA

    Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA
    Search for articles by this author
      The 2022 Danish study by Løkkegaard and colleagues showing an increased risk of dementia in women exposed to systemic estrogen therapy (ET) provides an opportunity to make some historical remarks [
      • Løkkegaard L.E.
      • Thinggard M.
      • Nygaard M.
      • Hallas J.
      • Osler M.
      • Christensen K.
      Systemic hormone therapy and dementia: a nested case-control and co-twin control study.
      ]. Our beliefs about the advantages and disadvantages of ET in relation to aging in general and aging of the brain in particular have changed quite dramatically over the last 30 years.

      Keywords

      Abbreviations:

      ET (Estrogen therapy), WHIMS (Women's Health Initiative Memory Study)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Løkkegaard L.E.
        • Thinggard M.
        • Nygaard M.
        • Hallas J.
        • Osler M.
        • Christensen K.
        Systemic hormone therapy and dementia: a nested case-control and co-twin control study.
        Maturitas. 2022; (this issue)
        • Rocca W.A.
        • Grossardt B.R.
        • Shuster L.T.
        Oophorectomy, estrogen, and dementia: a 2014 update.
        Mol. Cell. Endocrinol. 2014; 389: 7-12
        • Manson J.E.
        • Aragaki A.K.
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • Chlebowski R.T.
        • Howard B.V.
        • Thomson C.A.
        • Margolis K.L.
        • Lewis C.E.
        • Stefanick M.L.
        • Jackson R.D.
        • Johnson K.C.
        • Martin L.W.
        • Shumaker S.A.
        • Espeland M.A.
        • Wactawski-Wende J.
        Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials.
        JAMA. 2017; 318: 927-938
        • Savolainen-Peltonen H.
        • Rahkola-Soisalo P.
        • Hoti F.
        • Vattulainen P.
        • Gissler M.
        • Ylikorkala O.
        • Mikkola T.S.
        Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.
        BMJ. 2019; 364l665
        • Rocca W.A.
        • Mielke M.M.
        • Rocca L.Gazzuola
        • Stewart E.A.
        Premature or early bilateral oophorectomy: a 2021 update.
        Climacteric. 2021; 24: 466-473https://doi.org/10.1080/13697137.2021.1893686
        • Kaunitz A.M.
        • Kapoor E.
        • Faubion S.
        Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause.
        JAMA. 2021; 326: 1429-1430